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ABSTRACT
The increase in blood levels of GLP-1 with dietary resistant starch is thought to be
associated with the activities of hypothalamic NPY/AgRP neurons and the gene expression of
glucokinase in the ARC of the hypothalamus. Exendin-4 has been shown to be associated with
fatty acid synthesis and oxidation. In this project, it was proposed that 1) food intake will be
decreased in GLP-1R KO mice, the glucokinase (GK) mRNA expression in the liver and in the
hypothalamus, the hypothalamic NPY mRNA expression will be up-regulated by exendin-4
treatment; and 2) exendin-4 will decrease fatty acid synthesis and increase fatty acid oxidation.
In order to investigate these hypotheses, animal experiments were performed. Exendin-4
treated WT and GLP-1R KO mice were injected with exendin-4 at 100µg/Kg body weight or
vehicle for 7 days. The exendin-4 treated mice and the vehicle mice were subdivided into fed and
fasted groups. There were 8 groups of mice (n=8). Food intake after refeeding at 1h, 2h and 4h
was measured. At end of the study, the blood glucose level, the GK, CPT1, AOX1, SCD1, FAS,
SREBP1c and PPARγ mRNA expressions in liver, and the GK and NPY mRNA expressions in
hypothalamus were measured.
In this study, the food intake of GLP-1R KO mice at 1h, 2h and 4h was significantly less
than in WT mice, and the FAS expression in liver was significantly higher in GLP-1R KO mice
than WT mice. Exendin-4 treatment decreased blood glucose, and increased the GK gene
expression in liver, but not in the hypothalamus. The food intake and the NPY gene expression
were not altered by exendin-4. Only the AOX mRNA expression was increased by exendin-4.
CPT1, SCD1, FAS, SREBP1c, and PPARγ mRNA were not changed. GLP-1 might have
beneficial effects on improving the impairment of nutrient sensing system induced by aging. The
up-regulated FAS gene expression might be one possible mechanism for higher body fat in
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GLP1R KO mice. The lowering body fat storage effect of exendin-4 may be due in part to the
increase of the fatty acid oxidation in liver.
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CHAPTER 1
INTRODUCTION
Resistant starch, a non-digestible fermentable dietary fiber, has been shown in human
studies to have many health benefits. These include increasing satiety, reducing the blood
cholesterol and triglyceride levels, decreasing body fat, improving the insulin sensitivity, and
promoting anti-cancer effects (Robertson, Currie et al. 2003; Brown 2004; Higgins 2004).
Resistant starch also lowers fat storage in animals and significantly increases the expression and
release of glucagon-like peptide -1 (GLP-1) in the large intestine (Keenan, Zhou et al. 2006;
Zhou, Hegsted et al. 2006). GLP-1, one kind of satiety peptide, may inhibit food intake,
stimulates insulin release, decelerates the gastric emptying, reduces plasma glucose level, lowers
body weight and improves insulin sensitivity (Turton, O'Shea et al. 1996; Young, Gedulin et al.
1999; Meier, Gallwitz et al. 2003; Holst 2007). GLP-1 was thought to affect the activities of
hypothalamic NPY/AgRP neurons and it was demonstrated that the increase of NPY mRNA
induced by a 48h fast could be significantly attenuated by intracerebroventricular (icv) injection
of GLP-1 in rats (Seo, Ju et al. 2008).
Elderly persons are known to have impaired ability to adjust food intake following overeating or under-eating. Such age-related impairment of nutrient sensing is called anorexia of
aging, and is the reason that older people have an impaired ability to defend their body weight
(Roberts, Fuss et al. 1994; Hays and Roberts 2006). It has been found that aged rats had
decreased NPY responsiveness to fasting, so an impaired ability to defend body weight is
thought to be associated with the impaired activation of the hypothalamic NPY pathway
(Gruenewald, Marck et al. 1996; Kaneda, Makino et al. 2001). Obesity and aging have also been
shown to impair the nutrient sensing system in peripheral tissues such as muscle, liver, adipose
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and pancreas (Hajnoczky and Hoek 2007). Calorie restriction (CR) has been shown to reverse
such impairment of the nutrient sensing system in peripheral tissue (Dilova, Easlon et al. 2007).
It has been found that age-related impairment of glucose tolerance could be improved by
GLP-1 treatment (Wang, Perfetti et al. 1997). In our lab’s preliminary data, resistant starch was
found to increase gene expression of glucokinase in the ARC in the hypothalamus. Glucokinase
was thought to function as a glucose sensor to facilitate the adaptation in response to the
fluctuations in blood glucose levels (Roncero, Alvarez et al. 2000; Li, Xi et al. 2003; Roncero,
Alvarez et al. 2004). In our studies, we have observed increased (mice) or similar (rats) energy
intake for rodents fed resistant starch compared to rodents fed a diet with equal energy density.
Consistently high levels of GLP-1 and PYY as a result of fermentation of resistant starch may
overcome meal spikes of these hormones that would otherwise lead to satiety. Tolerance to PYY
may be the mechanism by which RS induces food intake (Zhou, Martin et al. 2008). It was
recently reported that repeated i.p. infusions of PYY increased food intake (Reidelberger, Haver
et al. 2008). Our observations are consistent with a report that dietary resistant starch did not
suppress appetite(Scribner, Pawlak et al. 2008). We hypothesize that resistant starch will mimic
the effects of calorie restriction. We expect the increasing of GLP-1 by resistant starch could
improve the impairment of nutrient sensing system induced by obesity and aging.
Exendin-4, a long-acting GLP-1 receptor agonist, has a much longer circulating and
biological half-life and is thought to be more potent than GLP-1 (Deacon, Pridal et al. 1996;
Szayna, Doyle et al. 2000). Exendin-4, just as GLP-1, inhibits the food intake, stimulates insulin
release, decreases plasma glucose level, reduces body weight and improves insulin sensitivity
(Young, Gedulin et al. 1999; Szayna, Doyle et al. 2000; Parkes, Pittner et al. 2001). Exendin-4
was also demonstrated to be associated with fatty acid metabolism. The key regulators of de
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novo hepatic lipogenesis, SREBP-1c, SCD1, ACC, PPAR-γ1, 2, and FAS were down-regulated,
and the key elements in β-oxidation of free fatty acids, PPARα and AOX were up-regulated by
exendin-4 treatment (Ding, Saxena et al. 2006; Samson, Gonzalez et al. 2008).
In this study, we investigated the effects of exendin-4 and GLP-1 receptor knock out on the
nutrient sensing system and fatty acid metabolism. The hypothesis for this work is that 1) the
food intake will be decreased in GLP-1R KO mice, the glucokinase (GK) mRNA expression in
the liver and in the hypothalamus, the hypothalamic NPY mRNA expression will be up-regulated
by exendin-4 treatment; and 2) exendin-4 can decrease fatty acid synthesis and increase fatty
acid oxidation. To test this hypothesis, we measured food intake, the expressions of GK, CPT1,
AOX1, SCD1, FAS, SREBP1c and PPARγ mRNA in liver, and the GK and NPY mRNA
expressions in hypothalamus in WT mice and GLP-1R KO mice with vehicle or exendin-4
treatment.
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CHAPTER 2
REVIEW OF LITERATURE
Glucagon-Like Peptide-1(GLP-1)
GLP-1, a gut peptide, comes from the preproglucagon gene product in the L cells of the
intestine. It is released in response to nutrients, such as FFA and carbohydrate (Badman and Flier
2005). This response occurs within minutes of food ingestion, even though the L cells are in the
distal intestine (Roberge and Brubaker 1993). The circulating half-life of GLP-1 is only 2 min as
GLP-1 can be quickly inactivated by the enzyme dipeptidyl peptidase IV (DPP-IV) (Kieffer,
McIntosh et al. 1995). This peptide has several functions which includ inhibiting food intake,
lowering body weight, decelerating the gastric emptying, stimulating insulin release, reducing
plasma glucose level and improving insulin sensitivity.
GLP-1 and Food intake: Intracerebroventricular (ICV) GLP-1 potently inhibits food intake
in fasted rats (Turton, O'Shea et al. 1996). Food intake was decreased and satiety was enhanced
by intravenously infused GLP-1 in both healthy subjects and patients with type 2 diabetes
(Gutzwiller, Drewe et al. 1999).
One study showed that when long-acting DPP-IV–resistant GLP-1 agonists were given
peripherally to rats, food intake and body weight both decreased (Larsen, Fledelius et al. 2001).
Exendin-4, a long-acting GLP-1 receptor agonist, results in immediate reduction in food intake
after 5 days of once daily injections and also produces a sustained reduction in food intake and
weight-gain when given twice daily injections for a total of 56 days in Zucker fatty rats (Szayna,
Doyle et al. 2000).
Exendin (9-39), a specific GLP-1-receptor antagonist, blocks the effects of ICV injected
GLP-1 on food intake. However, it only had effects on satiated rats, not on fasted rats. It
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increased the food intake more than double in satiated rats (Turton, O'Shea et al. 1996). Another
study also showed that exendin (9-39) could augment 1-h food intake by 300% after three
repeated injections every 20 min in satiated animals (Schick, Zimmermann et al. 2003).
The vagal-brainstem-hypothalamic pathway is necessary for the GLP-1 inhibitory effect on
food intake as this effect is abolished by ablation of this pathway (Abbott, Monteiro et al. 2005).
GLP-1 also functions at lateral and medial hypothalamic sites to reduce food intake (Schick,
Zimmermann et al. 2003).
The GLP-1 inhibitory effect on food intake is thought to be through the activities of
hypothalamic NPY/AgRP neurons. NPY and AgRP are both potent orexigenic neuropeptides,
and involved in control of food intake. Food intake, and the increased gene expression of NPY
and AgRP are induced by 48h fasting and are significantly attenuated by the
intracerebroventricular (icv) injection of GLP-1 in rats (Seo, Ju et al. 2008). Exendin (9-39) has
also been found to increase the feeding response to NPY (Turton, O'Shea et al. 1996).
But in our lab’s preliminary data, resistant starch which could significantly increases the
expression and release of glucagon-like peptide -1 (GLP-1) in the large intestine, did not inhibit
the food intake. Actually, resistant starch could significantly increase the cumulative food intake.
One reason might be the time and dosage differences. The food intake inhibitory effect of GLP-1
on 48-h fasted rats could be significant by one time single icv administration of GLP-1 (10µg)
(Seo, Ju et al. 2008). Food intake was decreased and satiety was enhanced by intravenously
infused GLP-1 (1.5 pmol. kg-1. min-1) for 2 days in both healthy subjects and patients with type
2 diabetes (Gutzwiller, Drewe et al. 1999). But in our study, rats were fed by resistant starch for
long-term and the GLP-1 levels were consistently higher over a 24-h period. Consistently high
levels of GLP-1 and PYY as a result of fermentation of resistant starch may overcome meal
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spikes of these hormones that would otherwise lead to satiety. Tolerance to PYY may be the
mechanism by which RS induces food intake (Zhou, Martin et al. 2008). It was recently reported
that repeated i.p. infusions of PYY increased food intake (Reidelberger, Haver et al. 2008). Our
observations are consistent with a report that dietary resistant starch did not suppress appetite
(Scribner, Pawlak et al. 2008). Another reason might be that resistant starch had increased
energy expenditures. The resistant starch fed mice might compensate the increased energy
expenditure by increasing food intake. These results strongly support our hypothesis that
resistant starch fed animals might have better adjustment for fasting, thus could help to attenuate
anorexia of aging. This study is focused on the age-associated anorexia.
GLP-1 and Obesity: GLP-1 reduces body weight 6 days after ICV injection, and exendin(9-39) increases body weight after 3 days ICV injection. Interestingly, the increase in body
weight when exendin-(9-39) and NPY were given together was significantly higher than when
given NPY alone (Meeran, O'Shea et al. 1999). Exendin (9-39) was thought to increase the
feeding response to NPY (Turton, O'Shea et al. 1996).
It has been found that a novel long-acting injectable GLP-1 derivative, NN2211, could
reduce body weight in both normal rats and obese rats with obesity generated by neonatal
monosodium glutamate treatment (MSG) (Abbott, Monteiro et al. 2005). Five days prandial
subcutaneous injections of recombinant glucagon-like peptide-1 (7-36) reduces body weight in
healthy obese subjects (Naslund, King et al. 2004). Peripheral infusions of glucagon-like
peptide-1 inhibit food intake, decrease carbohydrate oxidation and gastric emptying rate in
healthy obese subjects (Flint, Raben et al. 2001). However, GLP-1 receptor -/- mice, have
normal body weight and normal feeding behavior, even for 11- and 16-month-old GLP-1R-/-
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mice fed with high fat diet (Scrocchi and Drucker 1998). However, GLP-R-/- in our lab had
more body fat (unpublished data).
GLP-1 and Diabetes: The binding of GLP-1 to its receptors increases the levels of β cell
intracellular cAMP and insulin gene transcription. GLP-1 also functions synergistically with
glucose to stimulate insulin release in a glucose dependent manner (Drucker, Philippe et al. 1987;
Holz, Kuhtreiber et al. 1993; Holst 2007).
GLP-1 enhances cell proliferation of the endocrine and exocrine components of the
pancreas, decreases apoptotic cells within the islet as well in the exocrine pancreas, reduces the
caspase-3 expression, increases insulin content, and also decreases the fragmented nuclei in the
islet cells in Zucker diabetic rats (Farilla, Hui et al. 2002).
Exogenous GLP-1 decelerates gastric emptying after solid and liquid meals and increases
the meal retention time in the distal stomach in healthy subjects (Little, Pilichiewicz et al. 2006).
Exogenous GLP-1 also slows gastric emptying after solid meals and normalizes glucose
concentrations in patients with type 2 diabetes (Meier, Gallwitz et al. 2003).
Exendin-4, which has 53% sequence similarity to glucagon-like peptide (GLP)-1, decreases
blood glucose levels, reduces body weight and improves insulin sensitivity in obese diabetic
(ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)
(Young, Gedulin et al. 1999). Continuous subcutaneous infusion of GLP-1 for 6 weeks decreases
fasting and 8 h mean plasma glucose and free fatty acids, reduces body weight, and improves
insulin sensitivity and beta-cell function in patients with type 2 diabetes (Zander, Madsbad et al.
2002).
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Figure 1. The effects of GLP-1
The overall effects and metabolic actions, β cell function, and CNS function of GLP-1 are
illustrated in Figure 1 (Drucker 2003).
Glucagon-Like Peptide-1 Receptor -/- Mice
Glucagon-like peptide-1 receptor -/- mice were first generated in the Drucker lab in 1995 in
order to investigate the physiological importance of GLP-1. Although GLP-1 was thought to
inhibit food intake, there were no significant differences in 2-hour and 6-hour food intake after a
20-hour fasting in either female or male GLP-1R-/- mice compared to WT mice. In addition
there were also no significant differences in body weight for both female and male GLP-1R-/mice from 4 to 24 weeks of age compared to WT mice (Scrocchi, Brown et al. 1996). There was
also no evidence of abnormal body weight in 11- and 16-month-old aging GLP-1R-/- mice, or
obesity in GLP-1R-/- mice after 18 weeks of high fat feeding (Scrocchi and Drucker 1998). So,
in vivo the body weight and feeding behavior were not connected to the disruption of
GLP1/GLP1R signaling in the central nervous system.

8

But in our lab’s preliminary data, GLP-1R KO male mice had significantly higher body
weight and higher body fat compared with WT male mice after 12 weeks EC or RS diet feeding.
But before the EC or RS diet feeding, these GLP-1R KO male mice which were fed on chow diet
had the similar body weight and body fat compared with WT male mice. And GLP-1R KO
female mice which were fed consistently chow diet had similar body weight compared with WT
female mice. These reflects that the diet type might influence the body weight gain of GLP-1R
KO mice.
Following an oral glucose challenge or intraperitoneal glucose challenge, GLP1R-/- mice
have abnormal blood glucose tolerance and decreased levels of circulating insulin (Scrocchi,
Brown et al. 1996). There was no evidence for deterioration of glucose tolerance in 11- and 16month-old aging GLP-1R-/- mice, but it did result in increased insulin secretion during testing
for glucose tolerance, indicating that there may be a change in insulin sensitivity. In addition no
evidence for deterioration in glucose tolerance was detected in GLP-1R-/- mice after 18 weeks of
high fat feeding (Scrocchi and Drucker 1998). Therefore, GLP1/GLP1R signaling was related to
a modest glucose intolerance.
Compared with the WT mice, the GLP-1R -/- mice had an elevated glucose-dependent
insulinotropic polypeptide (GIP) secretion and enhanced GIP action after an oral glucose
tolerance test. Compared with the WT mice, the GLP-1R -/- mice had higher insulin response to
GIP perfusion of the pancreas and isolated islets when the glucose level was higher. The GLP-1R
-/- mice still had normal glucagon secretion. Such compensatory changes in the GIP secretion
and action in GLP-1R -/- mice, appears to account for the modification of the anticipated
phenotype resulting from interruption of the GLP1/GLP1R signaling pathway (Pederson,
Satkunarajah et al. 1998).
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Exendin-4
Exendin-4, which is isolated from the Gila monster salivary gland, is a 39-amino acid
peptide, and is a long-acting GLP-1 receptor agonist (Goke, Fehmann et al. 1993). Compared
with GLP-1, exendin-4 has a much longer circulating and biological half-life and is thought to be
more potent (Deacon, Pridal et al. 1996; Szayna, Doyle et al. 2000).
Compared with untreated animals, exendin-4 had an immediate reduction in food intake
after 5 days of once daily injections in Zucker fatty rats. When Zucker fatty rats were treated
with twice daily injections for a total 56 days, exendin-4 produced a sustained reduction in food
intake and weight-gain. After 4 weeks of exendin-4 treatment, Zucker fatty rats began to have
reduced fat deposition in the subcutaneous region of the abdominal region. Then after 8 weeks of
exendin-4 treatment, the visceral fat deposition began decreasing (Szayna, Doyle et al. 2000).
Exendin-4 increases the basal and glucose-stimulated insulin release in static incubation of
isolated islets, in dynamically perfused isolated islets and also in anesthetized rats. The
insulinotropic effects of exendin-4 occurs both in vitro and in vivo (Parkes, Pittner et al. 2001).
Exendin-4 increased the differentiation and proliferation of beta-cells in normal rats. The
regeneration of the pancreas and expansion of beta-cell mass were also enhanced with exendin-4
treatment in the partial pancreatectomy rat model of type 2 diabetes (Xu, Stoffers et al. 1999).
Treatment of Wistar diabetic rats with exendin-4 from postnatal day 2 to day 6 increases body
weight, beta-cell mass and pancreatic insulin content, reduces basal plasma glucose on day 7.
Treatment with exendin-4 from postnatal day 2 to day 6 resulted in the basal plasma glucose
level and plasma glucose clearance rates which were much better even at 2 months of age. This
suggested that exendin-4 had both short- and long-term beneficial effects on beta-cell mass

10

recovery and glucose homeostasis when given during the neonatal diabetic period (Tourrel,
Bailbe et al. 2001).
The antidiabetic effect of exendin-4 has been tested in several animal models of type 2
diabetes. Exendin-4 reduces body weight, blood glucose levels and improves insulin sensitivity
in hyperglycemic db/db and ob/ob mice, diabetic rhesus monkeys, and diabetic fatty Zucker rats
(Young, Gedulin et al. 1999).
The antidiabetic effect of exendin-4 has also been tested in healthy volunteers, and patients
with type 1 and type 2 diabetes. Exendin-4 delays gastric emptying, decreases food intake,
decreases fasting blood glucose levels and decrease the peak change of postprandial glucose
level in healthy volunteers (Edwards, Stanley et al. 2001). In patients with type 1 diabetes,
exendin-4 treatment 15 min before breakfast delays gastric emptying, reduces blood glucose
levels, blood pancreatic polypeptide, and glucagon levels after breakfast (Dupre, Behme et al.
2004). Exendin-4 also delays gastric emptying, reduces postprandial blood glucose levels, and
decreases insulin and glucagon levels following twice daily subcutaneous injections with meals
for 5 d in patients with type 2 diabetes (Kolterman, Buse et al. 2003). Additionally,
hyperglycemic patients with type 2 diabetes who were unable to control blood glucose level even
with maximally effective doses of combined metformin-sulfonylurea therapy, exendin-4
significantly decreased A1C and body weight in a 30-week, double-blind, placebo-controlled
study (Kendall, Riddle et al. 2005).
Exendin-4 alters fatty acid metabolism. Exendin-4 reduced body weight, decreased fat
content in liver tissue, reduced hepatic oxidative stress, and reversed hepatic steatosis in ob/ob
mice with 60 days of treatment. The key regulators of de novo hepatic lipogenesis, SREBP-1c
and SCD1, was down-regulated, and the key element in β-oxidation of free fatty acids, PPARα,
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was up-regulated in the liver tissue of the ob/ob mice treated with exendin-4. Besides these three
genes, ACC, which is associated with de novo hepatic lipogenesis was down-regulated, and
AOX, which is associated with β-oxidation of free fatty acids, was up-regulated in rat
hepatocytes with exendin-4 treatment (Ding, Saxena et al. 2006). One group constructed a mouse
model with elevated steady-state levels of Ex4 by a single injection of a helper-dependent
adenoviral (HDAd) vector which expresses exendin-4 long-term in vivo. When such mice are fed
a high-fat-diet, they had lower body weight, improved glucose homeostasis, decreased hepatic
fat, lower liver total lipid and triglyceride levels and an improved adipokine profile compared
with mice without injected with a control vector. The ACC1, ACC2, SCD1, FAS, and PPAR-γ1,
2, which are associated with de novo hepatic lipogenesis were down-regulated in HDAd-Ex4
mice (Samson, Gonzalez et al. 2008).
Glucokinase (GK)
Glucokinase, also called hexokinase IV, is a glucose phosphorylating enzyme. It can
facilitate the following reaction: Glucose + ATP → glucose-6-phosphate + ADP (Iynedjian
1993). Compared with the other hexokinases, glucokinase has a lower affinity for glucose. Its
half-saturated point for glucose is about 8 mmol/L. Another important characteristic of
glucokinase is that it is not inhibited by its product, glucose-6-phosphate. These two
characteristics of glucokinase enable continued glucose phosphorylation and result in glucose
transport not being rate limiting in GK - containing cells. Also the type of GLUT in these cells is
not insulin dependent. Thus, the glucose phosphorylating reaction is a "supply-driven" reaction,
with the flow being driven by the glucose supply, not by the demand for glucose-6-phosphate.
These two characteristics also enable the glucose sensor function of glucokinase in GK containing cells (Matschinsky 1996).

12

At this time there are about 150 mutations of the glucokinase gene that have been found in
humans. Such mutations can lead to at least three kinds of syndromes. First, persistent
hyperinsulinemic hypoglycemia, it is thought to be associated with the activation of glucokinase.
Second, permanent neonatal diabetes, which happens when the newborns have two of the same
alleles are thought to be associated with the inactivation of glucokinase. Third, maturity-onset
diabetes of the young, occurs when the patient has one defective allele which is thought to be
associated with the inactivation of glucokinase. All these functional consequences which come
from GK gene mutations provide potent evidence for the glucokinase glucose-sensor concept
(Glaser, Kesavan et al. 1998; Davis, Cuesta-Munoz et al. 1999; Njolstad, Sovik et al. 2001;
Christesen, Jacobsen et al. 2002).
Mice with the global, or pancreatic beta-cell or hepatocyte-specific knockouts of GK had
been already developed. Mice with the global, or pancreatic beta-cell -specific knockouts of GK
die within a few days after birth from severe diabetes. Mice with hepatocyte-specific of GK
knockouts are viable, and only mildly hyperglycemic (Postic, Shiota et al. 1999).
In hepatocytes, the catalytic activity of glucokinase is regulated by glucokinase regulatory
protein. When the glucose concentration is low, glucokinase is bound to glucokinase regulatory
protein and stays in the nucleus. When the glucose concentration is high or fructose is low,
glucokinase will translocate to a free state in the cytoplasm. The effect of high glucose
concentrations is less potent and slower than the effect of fructose (Toyoda, Miwa et al. 1994;
Brown, Kalinowski et al. 1997). In hepatocytes, the primary inducer of glucokinase is insulin
(Bedoya, Matschinsky et al. 1986).
The primary inducer of glucokinase in pancreatic β cells is glucose (Liang, Najafi et al.
1992). The glucokinase expression that is driven by glucose can be regulated by many factors. It
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can be up-regulated by cAMP, biotin, retinoic acid and insulin, and down-regulated by
Ca2+ channel blockers (Sorenson and Brelje 1997; Cabrera-Valladares, German et al. 1999;
Romero-Navarro, Cabrera-Valladares et al. 1999; Fernandez-Mejia, Vega-Allende et al. 2001).
Glucokinase mRNA is also found in several rat brain regions, including the ventromedial
and arcuate nuclei of the hypothalamus and cerebral cortex. Such glucokinase may be similar to
pancreatic glucokinase, as it has an RNA splicing pattern of the glucokinase gene product in
pancreatic islets. Also, glucokinase regulatory protein mRNA is found in the rat brain. All these
findings suggest that the glucokinase in rat brain functions as the glucose sensor to facilitate the
adaptation of the brain in response to thefluctuations in blood glucose levels (Roncero, Alvarez
et al. 2000; Li, Xi et al. 2003; Roncero, Alvarez et al. 2004).
Neuropeptide Y (NPY)
NPY is a potent orexigenic neuropeptide. It has been reported that chronic central NPY
administration could lead to persistent hyperphagia, body weight gain, and a significant increase
in body fat accumulation (Jeanrenaud and Rohner-Jeanrenaud 2001). Up-regulation of NPY in
the arcuate nucleus of the hypothalamus can be found during fasting (Brady, Smith et al. 1990).
NPY can increase the net energy gain by many mechanisms. It can increase the food intake,
decrease energy expenditure, and can stimulate glucocorticoid and insulin secretion to increase
the deposition of triglycerides in white adipose tissue (Jeanrenaud and Rohner-Jeanrenaud 2001).
NPY-knock-out mice have normal body weight and adiposity (Erickson, Clegg et al. 1996).
However, the response to fasting for the NPY KO mice is a decreased food intake compared with
the WT mice (Bannon, Seda et al. 2000).
AgRP is another potent orexigenic neuropeptide. It can increase food intake and decrease
energy expenditure by antagonism of the melanocortin-3 receptor and melanocortin-4 receptor
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(Morton and Schwartz 2001). The NPY/AgRP system is very important in both short- and longterm control of energy balance through the regulation of many kinds of hormones and nutrients.
It has been demonstrated that if there is defective inhibition of NPY/AgRP neurons, there may be
hyperphagia, decreased energy expenditure of glucose and lipid metabolism, and obesity (Kalra,
Dube et al. 1999). It has also been reported that if NPY Y1 feeding receptors are blocked or
immunoneutralized AgRP, the ghrelin-induced feeding would be impaired (Asakawa, Inui et al.
2001).
The NPY receptors are G-protein coupled receptors. At this time, six receptors have been
isolated, NPY Y1–Y6, and for these six NPY receptors, the Y6 receptor is found only active in
mice, but inactive in primates and absent in rats (Inui 1999; Kalra, Dube et al. 1999). The NPY
Y1 and Y5 receptors are thought to be associated with the energy balance effects of NPY
(Stanley, Wynne et al. 2005).
The food intake inhibitory effect of GLP-1 was thought to be through the activities of
hypothalamic NPY/AgRP neurons. Food intake and the increased gene expression of NPY and
AgRP induced by 48h fasting were significantly attenuated by the ICV injection of GLP-1 in rats
(Seo, Ju et al. 2008). Exendin (9-39) has also been found to increase the feeding response to
NPY (Turton, O'Shea et al. 1996).
Carnitine Palmitoyltransferase 1 (CPT1)
The carnitine palmitoyltransferase 1 is located in the mitochondrial outer membrane. The
function of the carnitine palmitoyltransferase 1 is to transfer long-chain fatty acids from the
cytosol to the mitochondrial matrix, where they are used for energy production through betaoxidation (Murthy and Pande 1987; Bieber 1988). The up-regulation of the carnitine
palmitoyltransferase 1 in the liver by a peroxisome proliferator-activated receptor-α (PPARα)
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agonist leads to the stimulation of the mitochondrial beta-oxidation and the triglyceride (TG) lowering effect (Minnich, Tian et al. 2001).
The absence of the carnitine palmitoyl transferase 1 will lead to the decreased long-chain
fatty acid oxidation and ketogenesis, and increased urinary carnitine concentrations. And absence
of this enzyme activity in the liver will lead to severe hypoglycemia and even death although just
a few patients have been reported with carnitine palmitoyl transferase 1 deficiency. However,
this syndrome can be reversed by administration of medium-chain triglycerides (Bougneres,
Saudubray et al. 1981; Angelini, Trevisan et al. 1987; Vianey-Saban, Mousson et al. 1993).
In order to decrease the high risk of carnitine palmitoyl transferase 1 deficiency and prevent
potentially life-threatening complications, pre-symptomatic diagnosis is needed. The ratio of free
carnitine to the sum of palmitoylcarnitine and stearoylcarnitine [C0/(C16 + C18)] which is
obtained by electrospray ionization-tandem mass spectrometry (ESI-MS/MS), has been shown to
be very highly specific for carnitine palmitoyl transferase 1 deficiency and can be used for presymptomatic diagnosis (Fingerhut, Roschinger et al. 2001).
The rat model with decreased hypothalamic CPT1 activity has been developed by injection
of a ribozyme-containing plasmid which was used for down-regulation of the carnitine palmitoyl
transferase 1 gene or by injection of biochemical inhibitors of CPT1 into the third cerebral
ventricle. This model with decreased long-chain fatty acid oxidation and ketogenesis in selective
hypothalamic neurons can lead to substantially decreased food intake and endogenous glucose
production (Obici, Feng et al. 2003).
Aldehyde Oxidase 1 (AOX1)
Aldehyde oxidase 1, a xenobiotic metabolizing protein, produces hydrogen peroxide
superoxide under certain conditions (Wright, Vaitaitis et al. 1993). Alkane production, a
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lipoperoxidation products, was determined in isolated rat hepatocytes during ethanol metabolism
in order to study the role of aldehyde oxidase 1 in the pathogenesis of alcohol-induced
hepatotoxicity. The alkane production was decreased by the inhibition of aldehyde oxidase 1.
Thus it has been thought that aldehyde oxidase 1 may play an important role in the pathogenesis
of alcohol-induced liver injury as it produces free radicals during ethanol metabolism (Shaw and
Jayatilleke 1990). Reactive oxygen species (ROS) generated by aldehyde oxidase 1 also increase
cell damage and fibrogenesis (Pessayre, Mansouri et al. 2002).
Aldehyde oxidase 1 level is higher in rats fed a high fat diet when compared with rats fed
standard chow diet. Adiponectin suppresses aldehyde oxidase 1 protein through activating
peroxisome proliferator-activated receptor-alpha (PPAR-á), as such suppression is blocked by the
PPAR-á antagonist. Adiponectin protects the liver from obesity or alcohol induced steatosis
because it reduces the reactive oxygen species (ROS) through the inhibition of aldehyde oxidase
1 (Neumeier, Weigert et al. 2006). Aldehyde oxidase 1 is also very important for adipogenesis, as
there is impaired lipid storage and adiponectin release in the differentiated adipocytes when
aldehyde oxidase 1 is knocked-down in the preadipocytes (Weigert, Neumeier et al. 2008).
Stearoyl-CoA Desaturase 1 (SCD1)
Stearoyl-CoA desaturase 1, a key regulator of fatty acid composition, regulates a ratelimiting step in the synthesis of unsaturated fatty acids. Stearoyl-CoA desaturase 1 can catalyze
the formation of the monounsaturated fatty acids palmitoleyl- and oleyl-CoA from the saturated
fatty acids palmitoyl-CoA and stearoyl-CoA. The ratio of monounsaturated fatty acids to
saturated fatty acids plays a key role on the cell membrane fluidity and signal transduction. This
ratio is important for the regulation of cell growth and differentiation (Enoch, Catala et al. 1976;
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Wang, Yu et al. 2005). Dietary cholesterol, fatty acids, several hormones, and growth factors all
can influence the expression and activity of stearoyl-CoA desaturase 1 (Ntambi 1999).
There is a reduction in monounsaturated fatty acids, cholesterol, and phospholipid synthesis,
and an increase in saturated free fatty acids and triacylglycerol in stearoyl-CoA desaturase 1
knocked-down human lung fibroblasts. A change in the ratio of the monounsaturated fatty acids
to saturated fatty acids leads to a reduction of proliferation rate, abolition of anchorageindependent growth, and increased sensitivity to palmitic acid-induced apoptosis in a ceramideindependent manner. This suggests that stearoyl-CoA desaturase 1 plays an important role in
maintaining cellular lipid homeostasis (Scaglia and Igal 2005). Stearoyl-CoA desaturase 1 is also
essential for cellular cholesterol homeostasis because it is important in esterification of
cholesterol to cholesterol esters (Miyazaki, Kim et al. 2000).
Compared with the normal ob/ob mice, the stearoyl-CoA desaturase 1 deficient ob/ob mice
have lower body weight, increased energy expenditure, decreased liver triglyceride storage, and
decreased VLDL (very low density lipoprotein) production (Cohen, Miyazaki et al. 2002).
Compared with wild-type mice, stearoyl-CoA desaturase 1 knockout mice also have lower body
adiposity, increased insulin sensitivity, enhanced energy expenditure and increased oxygen
consumption. These suggests that stearoyl-CoA desaturase 1 deficiency was associated with
decreased lipid synthesis and increased lipid oxidation (Ntambi, Miyazaki et al. 2002).
High fat diet-induced hepatic insulin resistance in rats and mice is reversed by specific
knockdown of hepatic stearoyl-CoA desaturase 1 through reducing gluconeogenesis and
glycogenolysis. This suggests that stearoyl-CoA desaturase 1 is also essential for high fat dietinduced hepatic insulin resistance (Gutierrez-Juarez, Pocai et al. 2006).
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Fatty Acid Synthase (FAS)
The main function of fatty acid synthase is to catalyze the synthesis of long-chain saturated
fatty acids from acetyl-CoA and malonyl-CoA, in the presence of NADPH (Wakil 1989).
The systemic or intracerebroventricular inhibition of fatty acid synthase induces a reduction
of food intake and body weight through the inhibition of the expression of neuropeptide Y in the
hypothalamus. Fatty acid synthase is thought to be associated with feeding regulation and may be
a new target for treating obesity (Loftus, Jaworsky et al. 2000).
Fatty acid synthase is also thought to be associated with cancer development, as there is
increased expression of fatty acid synthase in many common human cancers. The inhibition of
fatty acid synthase may be potentially useful for cancer therapy (Camassei, Cozza et al. 2003;
Menendez, Vellon et al. 2004).
There is lower fatty acid synthase mRNA level and activity in heterozygous fatty acid
synthase +/- mice. These mice cannot survive. This suggests that fatty acid synthase is necessary
for embryonic development (Chirala, Chang et al. 2003).
The expression of fatty acid synthase is regulated by feeding of carbohydrates and insulin
level in animals. Upstream stimulatory factors (USF1 and USF2) interact with the E box motif on
fatty acid synthase promoter to up-regulate fatty acid synthase gene expression in liver during
carbohydrates feeding. This up-regulated fatty acid synthase gene expression induced by dietary
carbohydrates is dependent on USF1 and USF2, thus the response is severely delayed in USF1
and USF2 knock-out mice. Sterol response element binding protein 1 (SREBP1) also can
transcriptionally regulate the fatty acid synthase gene expression (Paulauskis and Sul 1989;
Casado, Vallet et al. 1999).
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Sterol Regulatory Element-Binding Protein-1c (SREBP1c)
Sterol regulatory element-binding protein-1c, a transcription factor mainly expressed in
liver, activates genes involved in glucose utilization and fatty acid synthesis (Kim, Kim et al.
2004). The expression of SREBP-1c is regulated by nutritional status, being down-regulated
during fasting and up-regulated after refeeding (Kim, Sarraf et al. 1998).
The induction of the expression of a family of genes involved in fatty acid synthesis by
high-carbohydrate diet is dependent on SREBP-1c, as such induction cannot be observed in
SREBP-1 knock-out mice (Shimano, Yahagi et al. 1999). In streptozotocin-induced diabetic
mice, the up-regulated expression of SREBP-1c by adenovirus in the liver can induce the upregulated expression of a family of genes involved in fatty acid synthesis (Becard, Hainault et al.
2001).
In streptozotocin-induced diabetic rats, the gene expression of SREBP-1c is very low in the
liver, but this low expression can be reversed significantly by insulin (Shimomura, Bashmakov et
al. 1999). SREBP-1c is thought to be associated with the insulin dependent hepatic glucokinase
expression. The expressions of SREBP-1c and hepatic glucokinase can both be up-regulated by
insulin. The up-regulated expression of SREBP-1c by adenovirus in the liver increases the
expression of hepatic glucokinase. The induction of the expression of hepatic glucokinase by
insulin and SREBP-1c can be blocked by the over-expression of the dominant negative mutant of
SREBP-1c. This suggests that SREBP-1c is essential for insulin-dependent hepatic glucokinase
expression (Becard, Hainault et al. 2001; Kim, Kim et al. 2004).
Transgenic mice with adipocyte-specific over-expression of SREBP-1c results in abnormal
adipose tissue differentiation, insulin resistance, diabetes mellitus, fatty liver and high blood
triglyceride level (Shimomura, Hammer et al. 1998). In many insulin resistance animal models,
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such as lipodystrophic and ob/ob mice, insulin receptor substrate-2 (IRS)-2(-/-) mice, and Zucker
obese fa/fa rats, the gene expression of SREBP-1c is up-regulated in liver (Kakuma, Lee et al.
2000; Shimomura, Matsuda et al. 2000; Tobe, Suzuki et al. 2001). SREBP-1c is thought to be
involved in insulin resistance, diabetes and hepatic steatosis.
Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ)
PPARγ, a transcription factor which is highly expressed in adipocytes, functions as a key
regulator of adiopocyte differentiation (Chawla, Schwarz et al. 1994; Tontonoz, Hu et al. 1994).
PPARγ can activate several genes to increase lipid uptake and adipogenesis by adipocytes. The
knockout of the PPARγ in adipose tissue of mice makes the mice unable to generate adipose
tissue and protects the mice from obesity and insulin resistance when fed a high fat diet (Jones,
Barrick et al. 2005).
PPARγ was found to be the receptor for the glitazones in 1995 (Lehmann, Moore et al.
1995) and the glucose lowering effect of glitazones was thought to be associated with the
activation of PPARγ (Willson, Cobb et al. 1996). The PPARγ agonists have been used clinically
to improve the glycemic control and enhance insulin sensitivity in type 2 diabetic patients. Now,
PPARγ serves as a target of multimodal insulin sensitizers, PPARγ agonists are now a promising
research area even when considering the side-effects on weight gain and fluid retention
(Rangwala and Lazar 2004; Pegorier 2005; Cho and Momose 2008).
There are several mechanisms for the insulin sensitizer effect of the PPARγ agonists. First,
the insulin sensitizer effect of PPARγ agonists may be due to the effect of PPARγ agonists on
lipid. PPARγ agonists stimulate several genes to increase fatty acids uptake, storage, and
oxidation in both white and brown adipose tissue, thus decreasing the circulating concentrations
of both esterified and nonesterified fatty acids and reducing lipid accumulation in non-adipose
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tissue (Shimkets ef al., 1999). These two factors both are involved in the development of insulin
resistance.
Second, PPARγ agonists can down-regulate the gene expression of tumor necrosis factor α
(TNFα) and leptin which are secreted by adipose tissue and are involved in glucose utilization
and/or production in other tissues (Hofmann, Lorenz et al. 1994; De Vos, Lefebvre et al. 1996;
Kallen and Lazar 1996).
Finally, PPARγ agonists can reduce the gene expression of pyruvate dehydrogenase kinase
4 (PDK4) in muscle, thus enhancing glucose oxidation in muscle. PPARγ agonists can decrease
the hepatic gluconeogenesis through down-regulating the expression of phosphoenolpyruvate
carboxykinase in liver. PPARγ agonists also can reduce fatty acid oxidation in muscle and liver
(Shimkets ef al., 1999). The effects of PPARγ agonists on fatty acids and glucose is shown in
Figure 2 (Kliewer, Xu et al. 2001).

Figure 2. The effects of PPARγ agonists
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CHAPTER 3
THE ROLE OF GLUCAGON-LIKE PEPTIDE-1 ON FOOD INTAKE, GLUCOKINASE
EXPRESSION AND FATTY ACID METABOLISM
Introduction
Resistant starch has been shown to lower fat storage in animals and significantly increase
gene expression of glucagon-like peptide -1 (GLP-1) (Keenan, Zhou et al. 2006; Zhou, Hegsted
et al. 2006). GLP-1 affects the activities of hypothalamic NPY/AgRP neurons, inhibits food
intake and lowers body weight (Turton, O'Shea et al. 1996; Young, Gedulin et al. 1999; Meier,
Gallwitz et al. 2003; Holst 2007). Elderly persons have impaired ability to control food intake
following over-eating or under-eating and such impaired ability is thought to be associated with
the impaired activation of the hypothalamic NPY pathway (Gruenewald, Marck et al. 1996;
Kaneda, Makino et al. 2001). Obesity and aging have been shown to impair the nutrient sensing
system in peripheral tissues such as muscle, liver, adipose and pancreas (Hajnoczky and Hoek
2007). In our lab’s preliminary data, resistant starch was found to increase gene expression of
glucokinase in the ARC in the hypothalamus, which was thought to function as the glucose
sensor to facilitate the adaptation in response to fluctuations of the blood glucose levels. We
expect that increased GLP-1 by resistant starch could improve the impairment of nutrient sensing
system induced by obesity and aging. Exendin-4, a long-acting GLP-1 receptor agonist, has also
been shown to be associated with fatty acid synthesis and oxidation (Ding, Saxena et al. 2006;
Samson, Gonzalez et al. 2008). We hypothesize that 1) the food intake will be decreased in GLP1R KO mice, the glucokinase (GK) mRNA expression in the liver and in the hypothalamus, and
the hypothalamic NPY mRNA expression will be up-regulated by exendin-4 treatment; and 2)
exendin-4 will decrease the fatty acid synthesis and increase the fatty acid oxidation. Therefore,
in this study we measured food intake, the GK, CPT1, AOX1, SCD1, FAS, SREBP1c and
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PPARγ mRNA expressions in liver, and the GK and NPY mRNA expressions in hypothalamus
in WT mice and GLP-1R KO mice with vehicle or exendin-4 treatment.
Materials and Methods
Animals
The original GLP-1R KO mice were provided by the Dr. Daniel J. Drucker lab in the
Samuel Lunenfeld Research Institute (SLRI). The mice used in this study were bred by Anne
Raggio. They were maintained in a temperature-controlled room (21-23 oC) on a 12 hour/12 hour
light/dark cycle. The light was on from 7AM-7PM. In the experiment, water was available ad
libitum. Food was also available ad libitum except for the fasting time.
All mice were housed, four mice per cage, in 6” x 10” x 5” standard plastic cages with
bedding to contain their urine and feces, and with wire mesh covers. Pelleted food was placed on
wire mesh covers by the researcher. A water bottle was placed on the wire mesh cover with a
mouthpiece inserted through a mesh hole. A plastic cover was put over the cage. The cages were
changed twice a week. The researchers could observe the mice in the transparent cages. Animal
protocols were approved by the Pennington Biomedical Research Institutional Animal Care and
Use Committee.
Exendin-4 Treatment
The exendin-4 groups were injected ip with exendin-4 at 100µg/Kg mouse body weight.
The exendin-4 was purchased from Amylin Pharmaceuticals, Inc., San Diego, CA. 5mg
Exendin-4 was dissolved in 500 ml sterile 0.9% NaCl. The final injection dosage was exendin-4
at 100µl/10g of mouse body weight. The saline groups were injected daily with saline at
100µl/10g mouse body weight.
Experimental Design
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Acclimation Period: day 1-7. The female C57BL/6J mice and the female GLP-1R KO mice
were both separated into two groups at day 1. The ages and the average body weight of each
group were not statistically significantly different. They were fed chow diet for one week to get
accustomed to the new environment after regrouping.
Treatment Period: day 8-15. The weights of the mice were measured at the beginning of day
8. Then the body weights were measured every two days. The female C57BL/6J mice and the
female GLP-1R KO mice were both divided into two groups, the saline group and the exendin-4
group. This meant there were two independent variables in a 2 X 2 factorial: type of mouse and
type of injection. There were a total of 4 groups (n=16). Injection was done at 3:00 pm at day 8,
9, 10, 11, 12. At 9:00 pm of day 12, all mice were fasted for 13 hours. Injection was done at 9:00
am on day 13 and re-feeding was started at 10:00 am. The food intakes of each group were
measured at 1h, 2h and 4h after re-feeding. Injection was done at 3:00 pm at day 14. At 9:00 pm
of day 14, half of the total 4 groups of mice were fasted for a minimum of 12 hours. At this point
the study experimental design became a 2 x 2 x 2 factorial with 8 groups of mice (n=8) and three
independent variables. The experimental design is shown in figure 3. Injection was done at
9:00am at day 15 and blood glucose levels were measured using the Freestyle Blood Glucose
Meter following injection. The mice were then sacrificed via decapitation and the brain and liver
were removed and stored at -80 oC.
Measurements of GK, CPT1, AOX1, SCD1, FAS, SREBP1c, PPARγ mRNA Expressions
in liver
RNA was extracted from liver tissue using TRIzol reagent. The liver tissue was cut into
small pieces and homogenized using a Polytron PT 1200E Tissue Homogenizer for 30- 60
seconds in 0.5ml TRIzol reagent. Then 0.5ml TRIzol reagent was added, and the samples

25

8

Unfasted

Saline
8

Fasted

C57BL/6J mice
Exendin-4

8
Unfasted
8
Fasted
8
Unfasted

Saline
8

Fasted

GLP-1R KO mice
Exendin-4

8
Unfasted
8
Fasted

Figure 3 Experimental design
vortexed and incubated at Room Temperature for 5-10 minutes. The homogenized sample was
then centrifuged at 12,000 g for 10 minutes at 4oC and then transferred the supernatant (TRIzol
reagent layer) which contained RNA to a fresh tube. The next step was the addition of 0.2 ml
Chloroform, then the sample was vortexed and incubated at Room Temperature for 2-15 minutes.
This was followed by centrifugation at 12,000 g for 15 minutes at 4oC and the supernatant
(aqueous phase) which contained RNA was transfered to a fresh tube. The addition of 0.5 ml
isopropyl alcohol followed, and then the sample was vortexed and incubated at room temperature
for 5-10 minutes. Centrifugation followed at 12,000 g for 10 min at 4oC, and then the supernatant
was removed and the gel-like pellet at the bottom of the tube was kept. To the pellet 1 ml of 75%
ethanol was added to wash the pellet. Then the sample was centrifuged at 7500 g for 5 min at
4oC, and the 75% ethanol was removed and the gel-like pellet was again kept. The pellet was air-
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dried at 4oC for 5-10 min (the RNA pellet was not allowed to dry completely) and the RNA
pellet was dissolved in 200 µl RNase-free water. The RNA was then stored at -80 oC.
Two µl of sample RNA was used for RNA quantification using the nanodrop (Nanodrop
Technologies, Spectrophotometer ND-1000 UV/Vis). The RNA samples were diluted to 500 ng
/µl. Then 2 µl of these samples RNA was used for RNA quantification using the nanodrop again
to check the RNA concentration. Then all these RNA samples were diluted to 50 ng/ µl.
The quality of the RNA was measured by electrophoresis using an agarose gel. The gel
contains 1 g agarose in 100 ml 0.5 X TBE buffer (45 mM Tris base, 45 mM boric acid, 1 mM
EDTA pH 8.0) and 10 ul 50 mg/ml ethidium bromide, was cooled to 60°C. Sample were
electrophoresed in 6 X native agarose gel loading buffer (10 mM Tris-HCl (pH 7.6), 0.03%
bromophenol blue, 0.03% xylene cyanol FF, 60% glycerol, 60 mM EDTA at 160V for 10min.
The 28S and 18S RNA bands were visualized using the Bioaid gel documentation.
Real-time reverse transcriptase polymerase chain reaction was performed to measure the
mRNA levels of GK, CPT1, AOX1, SCD1, FAS, SREBP1c, and PPARγ in the liver samples.
Results were expressed as the ratio of the GK, CPT1, AOX1, SCD1, FAS, SREBP1c, PPARγ to
the constitutive gene cyclophilin. Taqman RT-PCR primers and probes were used. The primers
and probes used were CPT1, Mm00550438_m1; AOX1, Mm 00437475_m1; SCD1, Mm
00772290_m1; FAS, Mm 00662319_m1; SREBP1, Mm 00550338_m1; PPARγ, Mm
00440945_m1. The real time RT-PCR reagents were purchased from Applied Biosystems (Foster
City, CA). The real time RT-PCR reaction mixture contained 1ul of 10 X Tagman buffer, 5.5
mM MgCl2, 0.3 mM dATP, 0.3 mM dCTP, 0.3 mM dUTP, 0.3 mM dGTP, 500 nM forward
primers, 500 nM reverse primers, 200 nMTaqman probes, 0.3 U AmpliTaq Gold DNA
polymerase, 5 U MuLV reverse transcriptase, 7.5 U RNase inhibitor, and RNase-free water. For
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each gene, 3 µl 5 ng/ul liver template sample was used, total 15 ng. Each sample (total volume
10 µl) was performed in duplicate. RT-PCR conditions were 48 oC for 30 min, 95oC for 10 min
for one cycle, 95 oC for 15 sec and 60 oC for 1 min for 40 cycles.
Microdissection of Arcuate Nucleus (ARC) in Hypothalamus
The brains were rapidly obtained from the decapitated mice, then put on dry ice and
stored at -80 oC. The first step of the microdissection of the ARC was to dissect the middle brain
using a cryostat. Four continuous coronal sections from Bregman -1.22mm to -2.42mm were
collected for the ARC micropunch. Each coronal section was 300 um. The tubes were prepared
with 100 µl of 2- mecaptoethanol-lysis buffer (ratio is 0.7:100) before the micropunch. The
samples were then put on ice. A needle (Stoelting, Chicago, IL), which had an inner diameter of
0.52mm was used to perform the micropunch under a microscope. The tissue was transfered in
the needle immediately to the tube after the micropunch and vortexed to make the sample
homogenized. 100 µl cold 70% ethanol was added to the lysate and votexed about 10 seconds to
mix the sample thoroughly. The sample was put on the dry ice immediately and then stored at 80 oC until the RNA extraction was performed.
Measurements of GK, NPY mRNA Expression in Arcuate Nucleus (ARC) in the
Hypothalamus
The Absolutely RNA microprep kit (Stratagene, La Jolla, CA) was used to extract the
brain mRNA. First, the thawed sample was vortexed for about 10 sec, transfered to a seated
RNA-binding spin cup in a 2-ml collection tube, and centrifuged for 1 min at maximum speed at
4 oC. The filtrate was discarded, 600 µl of 1*low-salt wash buffer was added to the spin cup,
which was centrifuged for 1 min at maximum speed at 4 oC. Again, the filtrate was discarded,
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and centrifuged for 2 more min at maximum speed at 4 oC to make the fiber matrix dry. The
reconstituted RNase-free DNase I and DNase digestion buffer (ratio is 1:5) were mixed together
and 30 µl of the mixture was added directly onto the fiber matrix. The spin cup was incubated in
a 2-ml collection tube in 37 oC water bath for 15 min. 500 µl of 1*high-salt wash buffer was
added to the spin cup, and centrifuged for 1 min at maximum speed at 4 oC. The filtrate was
discarded, 600 µl of 1*low-salt wash buffer was added to the spin cup, and centrifuged for 1 min
at maximum speed at 4 oC. Again, the filtrate was discarded, 300 µl of 1*low-salt wash buffer
was added to the spin cup, and centrifuged for 2 min at maximum speed at 4 oC to make the fiber
matrix dry. The 2-ml collection tube was discarded, the spin cup was put in a new 1.5-ml
collection tube, and 20 µl of elution buffer was added directly onto the fiber matrix. This was
then centrifuged for 3 min at maximum speed at 4 oC after a 2-min incubation at room
temperature. The filtrate was collected and stored at -80 oC. 2 µl of brain mRNA was used for
mRNA quantification using the Nanodrop. The mRNA samples were diluted to 2 ng/µl.
Real-time reverse transcriptase polymerase chain reaction was performed to measure the
mRNA levels of GK and NPY in the brain samples. The ratio of the GK and NPY to the
constitutive gene cyclophilin was used to express the results. Taqman RT-PCR primers and
probes were used and the sequences of the primers and probes for mice cyclophilin and GK were
listed in Table 1. The mice NPY probe Ref. number was SS18395-01, the forward Ref. number
is SS18398-01, the reverse Ref. number is SS18398-02. The real time RT-PCR reagents were
purchased from Applied Biosystems (Foster City, CA). The real time RT-PCR reaction mixture
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contained 1ul of 10 X Tagman buffer, 5.5 mM MgCl2, 0.3 mM dATP, 0.3 mM dCTP, 0.3 mM
dUTP, 0.3 mM dGTP, 500 nM forward primers, 500 nM reverse primers, 200 nMTaqman probes,
0.3 U AmpliTaq Gold DNA polymerase, 5 U MuLV reverse transcriptase, 7.5 U RNase inhibitor,
and RNase-free water. For cyclophilin, 4 µl 2 ng/µl brain template sample, total 8 ng was used.
For the GK and NPY, 2 µl 2 ng/µl brain template sample, total 4ng was used. Each sample (total
volume 10 ul) was performed in duplicate. The real time RT-PCR condition was 48 oC for 30
min, 95oC for 10 min for one cycle, 95 oC for 15 sec and 60 oC for 1 min for 40 cycles.

Table 1. The sequences of primers and probes for real time RT-PCR.
F: forward primer, R: reverse primer, P: Taqman probe, CYC: cyclophilin, GK: glucose kinase.
Gene

Sequence

Mice CYC

F: 5'GGCCGATGACGAGCCC3'
R: 5'TGTCTTGGAACTTTGTCTGCAA3'
P: 5'TGGGGCCGCGTCTCCTTCGA 3'
-----------------------------------------------------------------------------------------------------------Mice GK
F: 5'CCACAATGATCTCCTGCTACTATGA3'
R: 5'AGCCGGTGCCCACAATC3'
P: 5'ACCGCCAATGTGAGGTCGGCA3'

Statistical Analysis
Data is presented as mean ± SEM. The significance of the differences between means was
analyzed by two-way ANOVA using the Statistical Analysis System (SAS 9.1). The significant
level was set at 0.05.
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Results
Food intake
The 1h, 2h and 4h food intakes were not affected by the exendin-4 treatment for either WT
mice or GLP-1R KO mice (P>0.05). But there was a significant reduction in fasting-refeeding
food intake (P<0.01) for KO mice at 1h, 2h and 4h compared to wild type by two way ANOVA.
(Figure 1)
FAS mRNA Expressions in liver
The FAS expression in liver was significantly higher in GLP-1R KO mice than WT mice in
unfasted condition (P<0.01). (Figure 2)
Blood glucose level
The blood glucose level was significantly reduced by exendin-4 treatment in the unfasted
condition for WT mice (P<0.0001). There were no effects of exendin-4 treatment for the fasted
condition and GLP-1R KO mice (P>0.05). Fasting significantly reduced the blood glucose level
of WT mice with vehicle treatment (P<0.0001). (Figure 3)
GK mRNA expression in liver
GK mRNA expression in liver was significantly up-regulated by exendin-4 treatment in
both unfasted and fasted condition for WT mice (P<0.001). As expected, there were no effects of
exendin-4 treatment for GLP-1R KO mice (P>0.05). (Figure 4)
CPT1, AOX1, SCD1, FAS, SREBP1c, PPARγ mRNA Expressions in liver
Exendin-4 had no effect on CPT1 mRNA expression in the liver samples, but increased the
AOX mRNA expression in the fasted condition in WT mice (P<0.05). mRNA expressions of
SCD1, FAS and SREBP1c, key regulators of denovo hepatic lipogenesis, were not changed by
exendin-4 treatment for WT mice (P>0.05). Exendin-4 also had no effect in PPARγ mRNA
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expression in the liver (P>0.05). Fasting significantly up-regulated fatty acid oxidation related
gene CPT1 and AOX1 expressions, down-regulated the fatty acid synthesis related genes SCD1,
FAS and SREBP1c expression, and up-regulated PPARγ mRNA expressions in the liver
(P<0.05). (Figure 5-10)
GK and NPY mRNA Expression in Arcuate Nucleus (ARC) in Hypothalamus
GK and NPY mRNA expressions in Arcuate Nucleus (ARC) in Hypothalamus were not
changed by exendin-4 treatment for WT mice and GLP-1R KO mice (P>0.05). (Figure 11-12)

Figure 1. Exendin-4 has no effect on the 1h, 2h and 4h food intake for both WT mice and GLP1R KO mice. There was a significant difference (P<0.01) for the mouse type in the 1h, 2h and 4h
food intake by two way ANOVA. There were no significant effects on the interaction (P>0.05).
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Figure 2. There was a significant difference (P<0.01) for the mouse type in FAS expression in
unfasted condition by two way ANOVA. Data are means ± SEM for 8 mice each group. The
fasting: P<0.0001, Interaction: P<0.01.
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Figure 3. Exendin-4 decreases the blood glucose level in the unfasted condition in WT mice, but
not in the fasted condition in GLP-1R KO mice. Data are means ± SEM for 8 mice each group.
In the unfasted condition, mice: P>0.05, drug: P<0.05, Interaction: P<0.0001 by two way
ANOVA. There were no significant effects on mouse type, drug, and interaction in the fasted
condition. For WT mice, fast: P<0.0001, drug: P<0.0001, Interaction: P=0.0001. For GLP-1R
KO mice, fast: P<0.05, drug: P<0.01, Interaction: P>0.05. *** P<0.0001 vs. controls for the WT
mice. * P<0.05 vs. controls for the GLP-1R KO mice.
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Figure 4. Exendin-4 increases the GK mRNA expressions of the liver samples in the unfasted
condition and fasted condition for the WT mice, but not for the GLP-1R KO mice. Data are
means ± SEM for 8 mice each group. In unfasted condition, mice: P<0.05, drug: P<0.01,
Interaction: P<0.01 by two way ANOVA. In fasted condition, mice: P>0.05, drug: P>0.05,
Interaction: P<0.0001. *** P<0.001 vs. controls for the WT mice.
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Figure 5. Exendin-4 has no effect in CPT1 mRNA expressions of the liver samples in the
unfasted condition and the fasted condition for both WT mice and GLP-1R KO mice. There were
significant effects of the fasting within the same treatment (vehicle or exendin-4), and for both
WT mice and GLP-1R KO mice. Data are means ± SEM for 8 mice each group. There were no
significant effects on mice, drug, and interaction in unfasted condition and fasted condition by
two way ANOVA. For both WT mice and GLP-1R KO mice, there was a significant fasting
effect (P<0.0001), but not an exendin-4 treatment effect (P>0.05) and no interaction effect
(P>0.05). *** P<0.0001 vs. controls within the same treatment (vehicle or exendin-4), and for
both WT mice and GLP-1R KO mice.
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Figure 6. Exendin-4 increases the AOX mRNA expressions of the liver samples in the fasted
condition in WT mice, but not for the unfasted condtion in GLP-1R KO mice. There were
significant effects of the fasting within the same treatment (vehicle or exendin-4), and for both
WT mice and GLP-1R KO mice. Data are means ± SEM for 8 mice each group. There were no
significant effects on mice, drug, and interaction in unfasted condition by two way ANOVA. In
fasted condition, mice: P<0.05, drug: P>0.05, Interaction: P<0.05. For WT mice, fast: P<0.0001,
drug: P<0.01, Interaction: P>0.05. For GLP-1R KO mice, fast: P<0.0001, drug: P>0.05,
Interaction: P>0.05. * P<0.05 vs. controls within the same treatment (vehicle or exendin-4), and
for both WT mice and GLP-1R KO mice.
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Figure 7. Exendin-4 has no effect in SCD1 mRNA expressions of the liver samples in the
unfasted condition and the fasted condition for both WT mice and GLP-1R KO mice. There was
only significant effects of fasting within the exendin-4 treatment for GLP-1R KO mice. Data are
means ± SEM for 8 mice each group. There were no significant effects on mice, drug, and
interaction in unfasted condition and fasted condition by two way ANOVA. For WT mice, fast:
P<0.05, drug: P>0.05, Interaction: P>0.05. For GLP-1R KO mice, fast: P<0.001, drug: P>0.05,
Interaction: P>0.05. * P<0.05 vs. controls within the exendin-4 treatment for GLP-1R KO mice.
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Figure 8. Exendin-4 has no effect in FAS mRNA expressions of the liver samples in the unfasted
condition and the fasted condition for both WT mice and GLP-1R KO mice. There were
significant effects of the fasting within the same treatment (vehicle or exendin-4), and for both
WT mice and GLP-1R KO mice. Data are means ± SEM for 8 mice each group. In unfasted
condition, mice: P<0.0001, drug: P>0.05, Interaction: P>0.05 by two way ANOVA. There were
no significant effects on mice, drug, and interaction in fasted condition. For both WT mice and
GLP-1R KO mice, there was a significant fasting effect (P<0.0001), but not an exendin-4
treatment effect (P>0.05) and no interaction effect (P>0.05). ** P<0.01 vs. controls within the
same treatment (vehicle or exendin-4), and for both WT mice and GLP-1R KO mice.
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Figure 9. Exendin-4 decreases the SREBP1c mRNA expressions of the liver samples in the
unfasted condition for GLP-1R KO mice, but not for the fasted condition and WT mice. Data are
means ± SEM for 8 mice each group. In unfasted condition, mice: P>0.05, drug: P<0.01,
Interaction: P>0.05 by two way ANOVA. In fasted condition, mice: P<0.0001, drug: P>0.05,
Interaction: P>0.05. For WT mice, fast: P<0.05, drug: P>0.05, Interaction: P>0.05. For GLP-1R
KO mice, fast: P<0.01, drug: P<0.01, Interaction: P<0.05. * P<0.05 vs. controls in unfasted
condition for GLP-1R KO mice.
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Figure 10. Exendin-4 has no effect in PPARγ mRNA expressions of the liver samples in the
unfasted condition and the fasted condition for both WT mice and GLP-1R KO mice. There were
significant effects of the fasting within the same treatment (vehicle or exendin-4), and for both
WT mice and GLP-1R KO mice. Data are means ± SEM for 8 mice each group. There were no
significant effects on mice, drug, and interaction in unfasted condition by two way ANOVA. In
fasted condition, mice: P<0.05, drug: P>0.05, Interaction: P>0.05. For both WT mice and GLP1R KO mice, there was a significant fasting effect (P<0.0001), but not an exendin-4 treatment
effect (P>0.05) and no interaction effect (P>0.05). *** P<0.0001 vs. controls within the same
treatment (vehicle or exendin-4), and for both WT mice and GLP-1R KO mice.
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Figure 11. Exendin-4 has no effect in GK mRNA expressions of the brain samples in the
unfasted condition and the fasted condition for both the WT mice and the GLP-1R KO mice.
There were no significant effects on mice, drug, and interaction in unfasted condition and fasted
condition by two way ANOVA.
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Figure 12. Exendin-4 has no effect in NPY mRNA expressions of the brain samples in the
unfasted condition and the fasted condition for both the WT mice and the GLP-1R KO mice. In
the unfasted condition, mice: P<0.0001, drug: P>0.05, Interaction: P>0.05 by two way ANOVA.
In the fasted condition, mice: P<0.05, drug: P<0.01, Interaction: P>0.05.
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Discussion
In this study, we investigated the effects of exendin-4 and GLP-1 receptor knock out on the
nutrient sensing system and fatty acid metabolism. We demonstrated that the food intake of
GLP-1R KO mice at 1h, 2h and 4h was significantly less than WT mice, and the FAS expression
in liver was significantly higher in GLP-1R KO mice than WT mice in unfasted condition.
Exendin-4 increases the GK expression in liver and increases the AOX expression in liver, which
was associated with β-oxidation of free fatty acids.
To our knowledge, GLP-1 might have beneficial effects on improving the impairment of
nutrient sensing system induced by aging. The up-regulated FAS gene expression might be one
possible mechanism for higher body fat in GLP1R KO mice. The lowering body fat storage
effect of exendin-4 may be in part due to increased fatty acid oxidation in the liver.
We measured the fasting-refeeding food intake at 1h, 2h and 4h for both WT mice and
GLP-1R KO mice. The food intake of GLP-1R KO mice at each time was significantly less than
WT mice. These data were consistent with our lab’s preliminary data. Resistant starch was found
to increase the fasting-refeeding food intake at 1h, 2h and 4h for 2 year old aged WT mice.
Elderly persons have impaired ability to adjust food intake following over-eating or undereating, resulting in impaired ability to defend their body weight (Roberts, Fuss et al. 1994; Hays
and Roberts 2006). It may be because they have decreased NPY responsiveness to fasting in
aged condition (Gruenewald, Marck et al. 1996; Kaneda, Makino et al. 2001). Resistant starch
significantly increased the expression and release of glucagon-like peptide -1 (GLP-1) in the
large intestine (Keenan, Zhou et al. 2006; Zhou, Hegsted et al. 2006). GLP-1R KO mice might
have similar impairment of nutrient sensing system as aged mice, so they are less responsive to
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fasting. All the data suggested that GLP-1 might have beneficial effects on improving the
impairment of nutrient sensing system induced by aging.
We compared the genes related to fatty acid metabolism between WT mice and GLP-1R
KO mice. We found that the FAS expression in liver was significantly higher in GLP-1R KO
mice than WT mice in unfasted condition. There are no previous reports for abnormal body
weight or feeding behavior of GLP1R KO mice, and even no evidence for abnormal body weight
in 11- or 16-month-old aging GLP-1R KO mice, or high fat feeding in GLP-1R KO mice
(Scrocchi, Brown et al. 1996; Scrocchi and Drucker 1998). But in our lab’s preliminary data,
GLP-1R KO male mice had significantly higher body weight and higher body fat compared with
WT male mice after 12 weeks EC or RS diet feeding. And the body fat percentage of GLP1R
KO mice is also significantly higher than WT mice. The up-regulated FAS gene expression
might be one possible mechanism for higher body fat in GLP-1R KO mice.
We measured the GK expression both in liver and in hypothalamus. We observed an
increase in the GK expression in liver by the exendin-4 treatment, but not in the hypothalamus.
In our lab’s preliminary data, resistant starch was found to increase gene expression of
glucokinase in the ARC in the hypothalamus. But in this preliminary study, rats were fed
resistant starch for 12 weeks and had consistently higher GLP-1 levels over a 24h period. In this
study, the mice were treated with exendin-4 for just 7 days. It is possible that an increase of GK
expression in the hypothalamus would require longer treatment with exendin 4.
In this study, we used a needle (Stoelting, Chicago, IL) which had an inner diameter of 0.52
mm to perform the micropunch of the arcuate nucleus of the slice of the brain under a
microscope. Then, we transfered the tissue in the needle immediately to the test tube after the
micropunch. The needle was so small that we did not get much tissue for the RNA extraction.
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The RNA concentrations of some samples were too low to do RT-PCR, resulting in missing
samples in each group. This may have affected the statistical results of the brain study.
Exendin-4 was demonstrated to be associated with fatty acid metabolism. Exendin-4
reduces body weight, decreases fat content of liver tissue, reduces hepatic oxidative stress, and
reverses hepatic steatosis in ob/ob mice with 60 days treatment. The key regulators of de novo
hepatic lipogenesis, SREBP-1c and SCD1, are down-regulated, and the key element in βoxidation of free fatty acids, PPARα, is up-regulated in the liver tissue of the ob/ob mice with 60
days exendin-4 treatment. Besides these three genes, ACC, which is associated with de novo
hepatic lipogenesis is down-regulated, and AOX, which is associated with β-oxidation of free
fatty acids, is up-regulated in rat hepatocytes with exendin-4 treatment (Ding, Saxena et al. 2006).
One group constructed a mouse model with elevated steady-state levels of exendin-4 by a single
injection of a helper-dependent adenoviral (HDAd) vector which expresses exendin-4
chronically in vivo. When such mice are fed a high-fat-diet, the single injection of HDAd vector
lowers body weight, improves glucose homeostasis, decreases hepatic fat, produces less liver
total lipid and triglyceride levels and improves the adipokine profile. The ACC1, ACC2, SCD1,
FAS, and PPAR-γ1, 2, which are associated with de novo hepatic lipogenesis are down-regulated
in HDAd-Ex4 mice (Samson, Gonzalez et al. 2008).
In our study, we only observed an increase in AOX mRNA expression, which would be
involved in fatty acid oxidation, in the fasted condition for WT mice. We did not see the effects
of exendin-4 treatment on CPT1 mRNA expression, or on mRNA expressions of SCD1, FAS
and SREBP1c, key regulators of denovo hepatic lipogenesis, and the PPARγ mRNA expression
in the liver samples. One possible reason is that in the previous two studies, one mouse model is
ob/ob, and the other is a high-fat-diet induced obese mouse model. In our study, we used a
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normal mouse model fed a chow diet. These wild type mice are lean and the fatty acid
metabolism may not be as active as the obese mice used in other studies. This could account for
their non- responsive to the exendin-4 treatment. Another possible reason is that in the two
previous studies, exendin-4 treatment was for 60 days in one, and in the other study the treatment
lasted 15 weeks. However, our study was only a short-term study with treatment for 7 days.
Many of the metabolic changes may not have had enough time to occur in our study. However,
the increase of AOX mRNA expression in our study suggested that the exendin-4 treatment
could increase fatty acid oxidation in liver.
In this study, we measured the NPY mRNA level in the arcuate nucleus in the arcuate
nucleus of the hypothalamus in both unfasted and fasted mice. But we observed no increase of
the NPY mRNA level in the fasting WT mice compared with the ad lib-fed WT mice (both
vehicle treatment) This is not consistent with other literature reports. For 2-3 months old male
mice, 24h food deprivation (fasting started at 7:00pm) increased hypothalamic NPY mRNA
about 108 ± 6%, and the refeeding for 6 h significantly decreased the hypothalamic NPY mRNA
level (Swart, Jahng et al. 2002). For 14-15 weekold male mice, 20h food deprivation (fasting
started at 5:00pm) increased the hypothalamic NPY mRNA about 31% (Boswell, Nicholson et al.
1999). Compared with the ad lib-fed male control rats, the gene expression of the prepr-NPY
mRNA in the arcuate nucleus was up-regulated by 43 ± 13% or 127 ± 29% after a 24 or 48 h
food deprivation (Schwartz, Sipols et al. 1993).
An important reason for differences in our study versus previous studies, may be the length
and timing of the fast. In this study, we fasted the mice at 9:00pm, 2 hours later after the lights
were turned off. But in the literature, they all initiated the fasting before the lights were out. So
the mice in our study had already eaten for 2 hours before fasting compared with other studies.
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Such fasting can be called mild fasting because the mice may have had high intakes in the first
two hours. Another reason may be that the mice in our study were about 3-5 months old, much
older than the mice in the previous studies. Maybe they were less responsive to the removal of
the food compared with the younger mice. Another possible reason may be the gender of the
mice. The female mice used in our study may be less responsive to the removal of the food
compared with the male mice used in other studies. So there ar plausible reasons why we did not
observe the increase of the NPY mRNA level in the fasting WT mice compared with the ad libfed WT mice.
A study showed that the increase of NPY mRNA induced by 48h fasting could be
significantly attenuated by the ICV injection of GLP-1 in rats (Seo, Ju et al. 2008). In our study,
the GLP-1 agonist, exendin-4 did not reduce the NPY mRNA level in both the unfasted and
fasted condition. The ICV injection of GLP-1 also dramatically inhibited the food intake in 48h
fasted rats (Seo, Ju et al. 2008). In 7-10 week old male mice, exendin-4 could significantly
reduced the 1h, 2h, 4h, 8h and 24h food intakes after 16-18h overnight fasting (Talsania, Anini et
al. 2005). But in our study, we did not observe the food intake inhibitory effects of exendin-4.
The food intake results are consistent with our NPY results. The reasons may be the same as why
NPY did not change after fasting. The values of the cumulative food intake at each time are
much lower in our study compared with the Talsania’s study for both vehicle treatments
(Talsania, Anini et al. 2005). The mice in our study were less hungry and so less responsive to
fasting and the exendin-4 treatment. These values also demonstrated that the mild fasting
designed in our study was the main reason why the food intake and NPY mRNA level were not
affected by the exendin-4 treatment.
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In conclusion, GLP-1 might have beneficial effects on improving the impairment of nutrient
sensing system induced by aging. The up-regulated FAS gene expression might be one possible
mechanism for higher body fat in GLP1R KO mice. The lowering body fat storage effect of
exendin-4 may be in part due to the increase of the fatty acid oxidation in liver. Our findings
provide a further understanding of the lowering of body fat storage effect of resistant starch, and
also show the possible beneficial effect of resistant starch on the nutrient sensing system.
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CHAPTER 4
CONCLUSIONS
The work in this thesis focuses on the effects of exendin-4 and GLP-1 receptor knock out on
the nutrient sensing system and fatty acid synthesis and oxidation. We measured the food intake,
GK, CPT1, AOX1, SCD1, FAS, SREBP1c and PPARγ mRNA expressions in liver, and the GK
and NPY mRNA expressions in hypothalamus in WT mice and GLP-1R KO mice with vehicle
or exendin-4 treatment. We showed that the food intake of GLP-1R KO mice at 1h, 2h and 4h of
re-feeding after a mild fast was significantly less than for WT mice, and the FAS expression in
liver was significantly higher in GLP-1R KO mice than WT mice in the unfasted condition.
Exendin-4 increased the GK expression in liver, but not in the hypothalamus. Exendin-4 had no
effects on the hypothalamic NPY expression and the 1h, 2h, 4h re-feeding food intake. We also
found that extendin-4 only increased the AOX expression in liver, which was associated with βoxidation of free fatty acids, but had no effect on the CPT1, SCD1, FAS, SREBP1c and PPARγ
mRNA expressions in liver, which are all key regulators of fatty acid metabolism.
We provide evidence to indicate that GLP-1 might have beneficial effects on improving the
impairment of the nutrient sensing system induced by aging. The up-regulated FAS gene
expression might be one possible mechanism for higher body fat in GLP1R KO mice. The
lowering of body fat storage effect of exendin-4 may be in part due to the increase of fatty acid
oxidation in liver. These findings help us understand the lowering of body fat storage effect of
resistant starch, and also introduce the possible beneficial effect of resistant starch on improving
the impairment of nutrient sensing system induced by aging.
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